Insulet Corp (PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Ticker
PODD
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical Devices
Market cap
$10.08B
52-week range
$126.40 - $354.88

Valuation

Share price
$139.98 (close of Nov 18, 2026)
P/E (TTM)
23.63x
Price to book
6.38x
Price to free cash flow
38.77x
Enterprise value
$10.46B
Book value per share
$22.77

Price performance

PeriodChange
1 day-3.69%
5 days-6.70%
1 month-0.79%
3 months-5.44%
6 months-8.20%
Year to date-50.75%
1 year-58.02%
3 years-19.58%
5 years-53.77%
10 years+276.39%
All time+777.07%

Short interest

As of
Oct 30, 2026
Short % of float
8.67%
Shares short
5.33M
Days to cover
4.25
Change since prior report
-5.39%
Source
FINRA consolidated short interest

Members of Congress who disclosed PODD trades

Markwayne Mullin · Gilbert Ray Cisneros · Tina Smith

Super investors holding PODD

Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
16.31%
Return on invested capital
15.48%
Return on assets
7.75%
Return on capital employed
18.87%
Gross margin
71.63%
Net margin
9.12%
EBITDA margin
20.83%
Revenue growth
30.73%
Net income growth
-40.93%
Free cash flow growth
23.71%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.58%
Current ratio
2.51x
Net debt to EBITDA
0.53x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$2.71B
Cost of revenue
$768.20M
Gross profit
$1.94B
EBITDA
$564.20M
Net income
$247.10M
Earnings per share
$3.51
Research and development
$301.10M
Interest expense
$59.40M
Shares outstanding
70.35M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$2.71B$1.94B$247.10M$3.51
2024-12-31$2.07B$1.45B$418.30M$5.97
2023-12-31$1.70B$1.16B$206.30M$2.96
2022-12-31$1.06B$805.60M$4.60M$0.07
2021-12-31$1.04B$752.10M$16.80M$0.25
2020-12-31$904.40M$582.30M$6.80M$0.11
2019-12-31$738.20M$480.30M$11.60M$0.19
2018-12-31$563.80M$370.20M$3.30M$0.06
2017-12-31$463.80M$277.20M-$26.80M-$0.46
2016-12-31$366.99M$211.09M-$28.88M-$0.48

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3171.63%9.12%16.31%15.48%
2024-12-3169.79%20.19%34.52%11.92%
2023-12-3168.35%12.16%28.16%9.86%
2022-12-3176.33%0.44%0.97%1.73%
2021-12-3172.28%1.61%3.02%6.64%
2020-12-3164.39%0.75%1.13%2.89%
2019-12-3165.06%1.57%15.28%4.80%
2018-12-3165.66%0.59%1.56%3.17%
2017-12-3159.77%-5.78%-16.91%-1.02%
2016-12-3157.52%-7.87%-45.77%-2.70%

Cash and debt by year

Period endCashDebt
2025-12-31$716.10M$930.80M
2024-12-31$953.40M$1.30B
2023-12-31$704.20M$1.37B
2022-12-31$689.80M$1.37B
2021-12-31$806.40M$1.25B
2020-12-31$947.60M$1.04B
2019-12-31$376.10M$887.90M
2018-12-31$288.94M$592.00M
2017-12-31$440.06M$566.17M
2016-12-31$298.57M$332.77M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$377.70M$62.70M
2024-12-31$305.30M$69.30M
2023-12-31$70.10M$48.40M
2022-12-31-$3.90M$40.90M
2021-12-31-$180.00M$34.40M
2020-12-31-$45.00M$35.90M
2019-12-31-$65.30M$28.70M
2018-12-31-$121.50M$37.50M
2017-12-31-$32.50M$31.90M
2016-12-31-$6.20M$23.62M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-04Sep 2026$1.59
2026-08-05Jun 2026$1.44
2026-05-06Mar 2026$1.14
2026-02-18Dec 2025$1.48
2025-11-06Sep 2025$1.13
2025-08-07Jun 2025$0.93
2025-05-08Mar 2025$0.81
2025-02-20Dec 2024$1.05

Filings and sources

Company website
insulet.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Globus Medical Inc (GMED) · Zimmer Biomet Holdings, Inc. (ZBH) · STERIS plc (STE) · Dexcom Inc (DXCM) · GE HealthCare Technologies Inc. (GEHC) · Edwards Lifesciences Corp (EW) · Boston Scientific Corp (BSX) · Stryker Corp (SYK)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades